Cancer

MK-1026

A Phase 2/3 Relapsed and/or Refractory Multiple Myeloma study

Trial overview

Disease

Haematology

Topic

MK-1026

Sponsor

MSD

Description

A Phase 2/3, Randomized, Open-Label Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Study details

For detailed information on this trial, please click here.

Trial status

Recruiting

Location

Principle Investigator

Dr Jaimal Kothari

MA, BM BCh, MRCP, FRCPath

Haematologist

Oxford +1